NASDAQ:UBX Unity Biotechnology (UBX) Stock Price, News & Analysis $1.47 +0.03 (+2.08%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.45▼$1.5150-Day Range$1.26▼$1.6352-Week Range$1.22▼$2.99Volume31,217 shsAverage Volume72,746 shsMarket Capitalization$24.68 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Unity Biotechnology alerts: Email Address Unity Biotechnology MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside308.2% Upside$6.00 Price TargetShort InterestHealthy2.02% of Float Sold ShortDividend StrengthN/ASustainability-0.60Upright™ Environmental ScoreNews Sentiment0.84Based on 3 Articles This WeekInsider TradingSelling Shares$2,262 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.74) to ($1.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.23 out of 5 starsMedical Sector166th out of 936 stocksPharmaceutical Preparations Industry69th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingUnity Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageUnity Biotechnology has only been the subject of 1 research reports in the past 90 days.Read more about Unity Biotechnology's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.02% of the float of Unity Biotechnology has been sold short.Short Interest Ratio / Days to CoverUnity Biotechnology has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Unity Biotechnology has recently decreased by 3.76%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldUnity Biotechnology does not currently pay a dividend.Dividend GrowthUnity Biotechnology does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUnity Biotechnology has received a 74.69% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for mental health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Unity Biotechnology is -0.60. Previous Next 3.2 News and Social Media Coverage News SentimentUnity Biotechnology has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Unity Biotechnology this week, compared to 0 articles on an average week.MarketBeat Follows3 people have added Unity Biotechnology to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Unity Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,262.00 in company stock.Percentage Held by InsidersOnly 5.80% of the stock of Unity Biotechnology is held by insiders.Percentage Held by InstitutionsOnly 29.49% of the stock of Unity Biotechnology is held by institutions.Read more about Unity Biotechnology's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Unity Biotechnology are expected to decrease in the coming year, from ($1.74) to ($1.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Unity Biotechnology is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Unity Biotechnology is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUnity Biotechnology has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Unity Biotechnology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupDave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Unity Biotechnology Stock (NASDAQ:UBX)Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.Read More UBX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart UBX Stock News HeadlinesJuly 24 at 11:45 AM | finance.yahoo.comUNITY Biotechnology Reports Granting of New Employment Inducement AwardJuly 22, 2024 | globenewswire.comUNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy OfficerJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! May 16, 2024 | markets.businessinsider.comBuy Rating on Unity Biotechnology: Promising Future for UBX1325 in Diabetic Macular Edema TreatmentMay 15, 2024 | investorplace.comUBX Stock Earnings: Unity Biotechnology Beats EPS for Q1 2024May 14, 2024 | globenewswire.comUNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business UpdatesApril 25, 2024 | globenewswire.comUNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual MeetingApril 23, 2024 | globenewswire.comUNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DMEJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! April 15, 2024 | investorplace.comUBX Stock Earnings: Unity Biotechnology Beats EPS for Q4 2023April 15, 2024 | globenewswire.comUNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdatesApril 9, 2024 | finance.yahoo.comUnity Biotechnology, Inc. (0YC0.L)February 17, 2024 | finance.yahoo.comUBX Mar 2024 2.000 callFebruary 7, 2024 | uk.investing.comUnity Biotechnology Inc (UBX)February 6, 2024 | finance.yahoo.comNew Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision LossDecember 29, 2023 | finance.yahoo.com10 Supplements for Longevity and Antiaging: Expert RecommendationsDecember 12, 2023 | finance.yahoo.comUNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DMENovember 27, 2023 | msn.comUnity Biotechnology (UBX) Price Target Increased by 8.33% to 6.63See More Headlines Receive UBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Unity Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:UBX CUSIPN/A CIK1463361 Webwww.unitybiotechnology.com Phone(650) 416-1192FaxN/AEmployees19Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$8.00 Low Stock Price Target$4.00 Potential Upside/Downside+308.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-104.21% Return on Assets-48.78% Debt Debt-to-Equity RatioN/A Current Ratio4.98 Quick Ratio4.98 Sales & Book Value Annual Sales$240,000.00 Price / Sales102.84 Cash FlowN/A Price / Cash FlowN/A Book Value$1.69 per share Price / Book0.87Miscellaneous Outstanding Shares16,790,000Free Float15,816,000Market Cap$24.68 million OptionableOptionable Beta0.84 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Anirvan Ghosh Ph.D. (Age 60)CEO & Director Comp: $940.4kDr. Nathaniel E. David A.B. (Age 56)Ph.D., Co-Founder & Executive Director Comp: $40kMs. Lynne Marie Sullivan (Age 58)CFO & Head of Corporate Development Comp: $663.63kMr. Alexander Hieu Nguyen J.D. (Age 47)Chief Legal Officer, Head of Operations & Corporate Secretary Comp: $589.4kDr. Jan M. van DeursenFounderDr. Judith Campisi Ph.D.FounderMr. Daohong Zhou M.D.FounderDr. Przemyslaw Sapieha Ph.D.Chief ScientistMs. Sharon Klier M.D.M.P.H., Head of Ophthalmology & Chief Development OfficerMore ExecutivesKey CompetitorsKezar Life SciencesNASDAQ:KZRAnixa BiosciencesNASDAQ:ANIXAclaris TherapeuticsNASDAQ:ACRSSagimet BiosciencesNASDAQ:SGMTInflaRxNASDAQ:IFRXView All CompetitorsInsidersAnirvan GhoshSold 1,214 sharesTotal: $1,699.60 ($1.40/share)Lynne Marie SullivanSold 324 sharesTotal: $453.60 ($1.40/share)Alexander Hieu NguyenSold 78 sharesTotal: $109.20 ($1.40/share)Anirvan GhoshSold 1,183 sharesTotal: $2,022.93 ($1.71/share)Anirvan GhoshSold 1,024 sharesTotal: $1,945.60 ($1.90/share)View All Insider Transactions UBX Stock Analysis - Frequently Asked Questions How have UBX shares performed this year? Unity Biotechnology's stock was trading at $1.93 at the start of the year. Since then, UBX shares have decreased by 23.8% and is now trading at $1.47. View the best growth stocks for 2024 here. How were Unity Biotechnology's earnings last quarter? Unity Biotechnology, Inc. (NASDAQ:UBX) issued its quarterly earnings data on Tuesday, May, 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.23. When did Unity Biotechnology's stock split? Unity Biotechnology shares reverse split on Thursday, October 20th 2022. The 1-10 reverse split was announced on Thursday, October 20th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Unity Biotechnology IPO? Unity Biotechnology (UBX) raised $85 million in an initial public offering (IPO) on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager. How do I buy shares of Unity Biotechnology? Shares of UBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Unity Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Unity Biotechnology investors own include NIO (NIO), Inseego (INSG), NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), VBI Vaccines (VBIV). This page (NASDAQ:UBX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unity Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unity Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free UBX Stock Alerts